Novavax's shares closed at $9.26 on Tuesday and fell to $6.90 in extended trading after reporting on its financial situation.
"We don't know what the strain selection is yet from FDA. We don't know what global health authorities may want from a regulatory standpoint on how the new vaccine needs to look," Jacobs said. "The sooner we know that, the more clarity we have on our path forward." Jacobs did not give a target for how deep spending or job cuts would be. Novavax has more than 1,500 employees, according to its website.Novavax is looking at all options that properly value its technology, pipeline and manufacturing capabilities on three continents, from partnerships to licensing deals to "different types of deals that could be much more significant," the CEO said.
Brought to you by Pfizer
Seriously
NO VAlue VAX
Shame. Novavax has been a good alternative for some of us to Pfizer. covid19nz
In USA.